ELVN Stock — Enliven Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being.

Source: 10-K FY2025 via SEC EDGAR

Share price

$51.01

Market cap

$3,753.9M

Cash

$884.4M

Enterprise value

$2,869.6M

Balance sheet

Cash	$884.4M
Debt	$0.0M
Net cash	$884.4M
Enterprise value	$2,869.6M
Basic shares	73.6M shares
Fully diluted shares	86.9M shares
Fully diluted market cap	$4,430.5M
Cash per share	$12.02
Quarterly burn	$18.5M
Cash runway	47.7 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.

Share structure

Common

73.3M

Pre-funded warrants

4.6M

Options

8.0M

RSUs

0.4M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.7M

FDSO

86.9M

Cap table as of 2026-10-28.

Price history

Loading ELVN daily closes…

Loading price history…

Next catalyst

ELVN-002 · Feb 12 - Mar 26 in 13 wks · Phase 1 · HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26 in 13 wks	ELVN-002	Phase 1	HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors	—
Jan 12 - Feb 23 in 14 mo	ELVN-001	Phase 1	Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Cml	—
Feb 12 - Mar 25 in 15 mo	ELVN-001	Phase 1	CML (Chronic Myelogenous Leukemia); Chronic Phase CML	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ELVN-001

Stage not disclosed · Active Modality: small molecule

Target BCR-ABL (ABL1)

Indications

Chronic Myeloid Leukemia (Phase 1)
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive (Phase 1)
Cml (Phase 1)

Status note Small molecule from the BCR-ABL program; preparations for a planned pivotal trial are underway. Indication and current trial stage not stated in the primary excerpts.

ELVN-002

Stage not disclosed · Terminated Modality: small molecule

Target HER2

Indications

HER2 Mutant Non-small Cell Lung Cancer (Phase 1)
HER2-positive Metastatic Breast Cancer (Phase 1)
HER2 Gene Mutation (Phase 1)

Status note The Company states it is exploring strategic alternatives for the ELVN-002 program and is no longer pursuing its development.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ELVN-001
Lead indication	Chronic Myeloid Leukemia (CML)
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06328738	Phase 1	Active, not recruiting	Sponsor	ELVN	—	HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors	—
NCT05304377	Phase 1	Recruiting	Sponsor	ELVN	—	Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Cml	—
NCT06787144	Phase 1	Recruiting	Sponsor	ELVN	—	CML (Chronic Myelogenous Leukemia); Chronic Phase CML	—
NCT05650879	Phase 1	Active, not recruiting	Sponsor	ELVN	—	HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Enliven Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	6,776,632	-1,182,906	6.51%	2026-08-14
Baker Bros. Advisors	905,191	no change	0.23%	2026-08-14
Logos Global Management	465,000	-75,000	1.02%	2026-08-14
ADAR1 Capital Management	387,718	+58,178	0.92%	2026-08-14
Cormorant Asset Management	150,000	+150,000	0.39%	2026-08-14
Ikarian Capital	126,541	+126,541	1.05%	2026-08-14
Sphera Biotech	112,765	-40,500	0.82%	2026-08-14
Great Point Partners	70,000	+70,000	0.84%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ELVN — Enliven Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ELVN — Enliven Therapeutics Inc.